Triple combo outperforms dual therapies in moderate-to-very severe COPD
In the treatment of patients with moderate-to-very severe chronic obstructive pulmonary disorder (COPD), triple treatment with budesonide, glycopyrrolate, and formoterol fumarate confers greater improvements in symptoms and health-related quality of life relative to dual therapies, according to data from the ETHOS trial.
